Compounded Semaglutide in 2026
A prescription GLP-1 medicine, prepared by a licensed pharmacy for one patient at a time. What semaglutide is, how it works, and where it legally stands in 2026.
Compounded semaglutide is a prescription medicine that a licensed pharmacy prepares for one patient at a time, using semaglutide, the GLP-1 peptide behind the recent shift in weight care. It is a compounded medication made to a prescription written for you. Here is what it is, how it works, and where it legally stands in 2026.
What compounded semaglutide is
Compounded semaglutide is a medication that a state-licensed 503A pharmacy prepares for a specific patient with a valid prescription, using the drug substance semaglutide. It is a compounded preparation: a pharmacy makes it to the dose a licensed physician orders for you, rather than a manufacturer producing finished branded pens at scale. It is pharmacy-grade, meaning prescribed and prepared under pharmacy standards, but it is not FDA-approved and has not been through FDA review.
It is a distinct medicine, not Ozempic or Wegovy, the FDA-approved branded semaglutide products made by Novo Nordisk. The way to compare a compounded prescription with the branded pens is on access, cost, and oversight, not on being the same drug.
How semaglutide works
Semaglutide is a GLP-1 receptor agonist, a peptide that mimics a hormone your body already makes. GLP-1, short for glucagon-like peptide-1, is released after you eat: it signals fullness to the brain, slows how quickly the stomach empties, and helps regulate blood sugar. Semaglutide is a modified, longer-lasting version of that signal, changed just enough chemically to last about a week in the body instead of the few minutes natural GLP-1 survives.
It is studied for weight management and type 2 diabetes. The important part to understand is that it does not force the body to do something new. It amplifies a satiety signal the body already uses, which is why it belongs to the same family of peptide messengers as insulin and oxytocin.
What "compounded" and "503A" mean
A 503A pharmacy is a state-licensed compounding pharmacy that prepares medications for individual, named patients with prescriptions. Every vial carries a label with your name, your prescriber, the dose, and an expiration date. Sterile injectables like semaglutide are made under United States Pharmacopeia standards for cleanroom preparation and testing, and each batch is documented.
This is the legitimate path for a personalized compounded medicine: a real prescription, a licensed pharmacy, and a record you can audit. It is the opposite of a "research-grade" vial ordered off a website, which we come back to below.
Is compounded semaglutide legal in 2026?
When it is done the individualized, prescribed way, yes, and the rules tightened in 2026. The FDA declared the semaglutide shortage resolved in February 2025, which ended the broad allowance that let compounders make large volumes during the shortage. Since then, the FDA has moved to restrict mass production of GLP-1 copies: it proposed removing semaglutide from the 503B outsourcing-facility bulk list in April 2026, and it limits pharmacies from routinely compounding simple copies of a commercially available drug.
What remains legitimate is individualized 503A compounding. A licensed physician determines that a compounded formulation is clinically appropriate for you, and a state-licensed 503A pharmacy fills that specific prescription. That is the path pru uses: everything it dispenses is compounded by a 503A pharmacy against a prescription written for you by a licensed physician. The line the law draws is between an individual, prescribed, pharmacy-made medicine on one side, and mass-produced copies or unprescribed research vials on the other.
How compounded semaglutide is taken
Semaglutide is a once-weekly injection. It is started at a low dose and increased gradually over several weeks to reduce side effects, a process called titration. The dose your physician sets, and how you reconstitute and inject it, matter a great deal: getting them wrong is the most common cause of problems with compounded vials. For the full titration chart and the step by step, see our guide to semaglutide dosage and how to use it.
Pharmacy-grade vs research-grade
One of the most important questions with any peptide is where the vial comes from. A pharmacy-grade compounded prescription and a "research-grade" vial sold online "for research use only" can carry the same word on the label and be very different things. A research vial has no prescription, no licensed pharmacy, and no clinician standing behind it. Pharmacy-grade means a licensed physician prescribed it, a 503A pharmacy prepared it, and a Certificate of Analysis documents what is in it.
| Compounded semaglutide | Branded semaglutide (Ozempic, Wegovy) | Research-grade vial | |
|---|---|---|---|
| What it is | A prescription medicine a 503A pharmacy prepares for one named patient. Not FDA-approved. | Novo Nordisk's finished, FDA-approved product, made at manufacturing scale. | A vial labeled "for research use only," not a prescribed or dispensed medicine. |
| Oversight | Licensed physician prescribes; state-licensed 503A pharmacy compounds; Certificate of Analysis on every vial. | Full FDA review and approval; manufactured under federal drug-manufacturing standards. | No prescriber, no licensed pharmacy, no clinician accountable for it. |
| How you get it | Clinical intake, physician review, and a prescription filled by a 503A pharmacy. | A prescription from your clinician, filled at a retail or specialty pharmacy. | Ordered directly online with no prescription and no medical review. |
Safety and how to choose a legitimate provider
With compounded semaglutide, the thing to get right is the source and the dose, not the peptide itself. Semaglutide has been studied for years for weight management and metabolic support. The real risks in this category come from two avoidable places.
The first is a dosing error, because compounded semaglutide is measured in milligrams but drawn in units on an insulin syringe, and getting that milligram-to-unit conversion right matters. The second is an unverified source, meaning a vial with no prescriber and no pharmacy behind it. A legitimate provider removes both risks by writing your exact dose for you and filling it through a real pharmacy.
So the first step is to vet the provider before you think about the molecule. A legitimate one clears every item below. If a seller skips any of them, that tells you what you need to know.
- A valid prescription. A licensed physician reviews your intake and writes your dose. No prescription means no medicine, only a grey-market vial.
- A state-licensed 503A pharmacy. The medicine is prepared for you by name by a licensed compounding pharmacy, not shipped from an anonymous lab.
- A Certificate of Analysis on every vial. This is independent lab documentation of the identity, strength, and purity of what is in the vial, so you are not guessing.
- LegitScript certification. This is a third-party certification that a healthcare or pharmacy operation meets legal and safety standards, and it is a fast trust signal you can check.
- Base semaglutide, not a salt form. The active ingredient should be base semaglutide, not semaglutide sodium or semaglutide acetate. The FDA has flagged those salt forms as a concern in compounding, so a legitimate provider uses the base form.
THE SHORT VERSIONA legitimate compounded semaglutide provider gives you a real prescription from a licensed physician, fills it at a state-licensed 503A pharmacy, provides a Certificate of Analysis, carries LegitScript certification, and uses base semaglutide rather than a sodium or acetate salt form. Those five checks are how you tell a prescribed medicine from a mystery vial.
503A versus 503B: what the difference means
503A and 503B are two different kinds of compounding, and the difference explains what is legitimate in 2026. A 503A pharmacy compounds a medication for a specific patient based on that patient's prescription. A 503B facility is a registered outsourcing facility that can compound in larger batches, often without a patient-specific prescription, under stricter federal manufacturing oversight. Both are legal categories. They just serve different purposes.
That distinction is why the shortage change mattered. The FDA declared the semaglutide shortage resolved in February 2025. Once a drug is off the shortage list, mass compounding of a copy of the branded product becomes restricted. But individualized 503A compounding on a valid prescription for a named patient remains legitimate. That patient-specific route is the one pru uses.
How pru does it
pru works with licensed physicians who prescribe and 503A pharmacies that fill, and it sells the peptide at cost. A simple intake matches you to a protocol, a physician reviews whether compounded semaglutide is appropriate for you, and if it is, a 503A pharmacy prepares your prescription with a Certificate of Analysis on every vial.
You pay the pharmacy's actual cost for the medicine, itemized, with no markup, funded by a flat membership rather than a marked-up drug. If you want compounded semaglutide done the legitimate, transparent way, that is what pru is built for. Start with semaglutide, browse the full weight loss and metabolism catalog, or see the at-cost pricing.
Common questions
Sources & further reading
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. fda.gov. (Shortage resolution and compounding limits.)
- U.S. Food and Drug Administration. Declaratory Order: Resolution of Shortages of Semaglutide Injection. fda.gov, February 2025.
- U.S. Food and Drug Administration. Proposed exclusion of semaglutide from the 503B bulk drug substances list. fda.gov, April 2026.
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers (503A vs 503B; compounded drugs are not FDA-approved). fda.gov.
- Novo Nordisk. Ozempic and Wegovy (semaglutide) prescribing information. (FDA-approved branded semaglutide.)
- pru pricing and catalog. joinpru.com. Accessed July 2026.
- U.S. Food and Drug Administration. Compounding and the FD&C Act Sections 503A and 503B. fda.gov.
- U.S. Food and Drug Administration. Certain Semaglutide Salt Forms Are Not the Same Active Ingredient as the Approved Semaglutide Base. fda.gov.
- LegitScript. Healthcare Merchant and Pharmacy Certification Standards. legitscript.com.